John Marchica
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
John Marchica has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Ranjan Perera
Department of Neurosurgery and Oncology, Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, Baltimore, USA
4 shared publications - Piyush Joshi
Hopp Children’s Cancer Center (KiTZ), Heidelberg, Germany
3 shared publications - Animesh Ray
Keck Graduate Institute
2 shared publications - Bongyong Lee
Drug Discovery Center, Daewoong Pharmaceutical Co., Ltd, Yongin, Korea
2 shared publications - Darren Finlay
Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, USA
2 shared publications - David C. Radley
Plymouth Hospitals NHS Trust, United Kingdom
2 shared publications
Latest Publications
- 1 February 2023
- Published by Springer Publishing Company
Jonas & Kovner’s Health Care Delivery in the United States
This comprehensive textbook contains information on a wide array of topics, including the organization of care, population health, the fundamental challenges of health disparities, health care financing and economics, and health information technology’s role in improving care and protecting privacy. New chapters on public health preparedness and its role in mitigating effects on health and the health system and the medical and social challenges of caring for older adults provide insight into important, ongoing challenges and what those challenges reflect about our system of care. With an increased emphasis on health disparities, population health, and health equity, this textbook includes a timely focus on how social and behavioral determinants influence health outcomes. Students will gain a deeper understanding of public health systems and their societal role and of the economic perspectives that drive health care managers and the system. Thorough coverage of the rapid changes that are reshaping our system, in addition to an evaluation of our nation’s achievement of health care value, will equip students with the critical knowledge they need to enter this dynamic and complex field. The book also includes cutting-edge, evidence-based information on preventive medicine, innovative approaches to control health care costs, initiatives to achieve high-quality and value-based care, and much more from prominent scholars, practitioners, and educators within health care management, public health, population health, health policy, medical care, and nursing.
- 1 February 2023
- Published by Springer Publishing Company
Jonas & Kovner’s Health Care Delivery in the United States
This comprehensive textbook contains information on a wide array of topics, including the organization of care, population health, the fundamental challenges of health disparities, health care financing and economics, and health information technology’s role in improving care and protecting privacy. New chapters on public health preparedness and its role in mitigating effects on health and the health system and the medical and social challenges of caring for older adults provide insight into important, ongoing challenges and what those challenges reflect about our system of care. With an increased emphasis on health disparities, population health, and health equity, this textbook includes a timely focus on how social and behavioral determinants influence health outcomes. Students will gain a deeper understanding of public health systems and their societal role and of the economic perspectives that drive health care managers and the system. Thorough coverage of the rapid changes that are reshaping our system, in addition to an evaluation of our nation’s achievement of health care value, will equip students with the critical knowledge they need to enter this dynamic and complex field. The book also includes cutting-edge, evidence-based information on preventive medicine, innovative approaches to control health care costs, initiatives to achieve high-quality and value-based care, and much more from prominent scholars, practitioners, and educators within health care management, public health, population health, health policy, medical care, and nursing.
- Open Access
- 1 February 2023
- Published by Springer Publishing Company
Health Care Financing, Costs, and Value
Health care costs are a burden for families, government, and employers. The United States needs to balance affordability of health care with investments in life-enhancing treatments. Health care industry is one of the largest parts of the American economy, accounting for over 20% of our gross domestic product. Medical care restores health more than it ensures a population is healthy over its life span. The United States has developed an insurance system to overcome the obstacle of high costs and pay for services collectively. Public insurance programs, such as Medicare, Medicaid, and Children’s Health Insurance Program (CHIP), and private insurance companies, such as UnitedHealthcare, Aetna, and Kaiser Permanente, work differently. A key question is how much should be spent on population health and how much on recovery-oriented medical care. Strategies and planning to keep people healthy could include public health initiatives, prevention initiatives, and social policies that make healthy choices possible and likely.
- 1 February 2023
- Published by Springer Publishing Company
Open AccessHealth Care Financing, Costs, and Value
Health care costs are a burden for families, government, and employers. The United States needs to balance affordability of health care with investments in life-enhancing treatments. Health care industry is one of the largest parts of the American economy, accounting for over 20% of our gross domestic product. Medical care restores health more than it ensures a population is healthy over its life span. The United States has developed an insurance system to overcome the obstacle of high costs and pay for services collectively. Public insurance programs, such as Medicare, Medicaid, and Children’s Health Insurance Program (CHIP), and private insurance companies, such as UnitedHealthcare, Aetna, and Kaiser Permanente, work differently. A key question is how much should be spent on population health and how much on recovery-oriented medical care. Strategies and planning to keep people healthy could include public health initiatives, prevention initiatives, and social policies that make healthy choices possible and likely.
- 8 June 2021
- Published by Springer Nature in Journal of Human Genetics
- Vol. 66 (11) , 1127-1137
Mapping genetic variability in mature miRNAs and miRNA binding sites in prostate cancer
MicroRNAs (miRNAs) regulate diverse cancer hallmarks through sequence-specific regulation of gene expression, so genetic variability in their seed sequences or target sites could be responsible for cancer initiation or progression. While several efforts have been made to predict the locations of single nucleotide variants (SNVs) at miRNA target sites and associate them with cancer risk and susceptibility, there have been few direct assessments of SNVs in both mature miRNAs and their target sites to assess their impact on miRNA function in cancers. Using genome-wide target capture of miRNAs and miRNA-binding sites followed by deep sequencing in prostate cancer cell lines, here we identified prostate cancer-specific SNVs in mature miRNAs and their target binding sites. SNV rs9860655 in the mature sequence of miR-570 was not present in benign prostate hyperplasia (BPH) tissue or cell lines but was detectable in clinical prostate cancer tissue samples and adjacent normal tissue. SLC45A3 (prostein), a putative oncogene target of miR-1178, was highly upregulated in PC3 cells harboring an miR-1178 seed sequence SNV. Finally, systematic assessment of losses and gains of miRNA targets through 3′UTR SNVs revealed SNV-associated changes in target oncogene and tumor suppressor gene expression that might be associated with prostate carcinogenesis. Further work is required to systematically assess the functional effects of miRNA SNVs.
- 8 June 2021
- Published by Springer Nature in Journal of Human Genetics
- Vol. 66 (11) , 1127-1137
Mapping genetic variability in mature miRNAs and miRNA binding sites in prostate cancer
MicroRNAs (miRNAs) regulate diverse cancer hallmarks through sequence-specific regulation of gene expression, so genetic variability in their seed sequences or target sites could be responsible for cancer initiation or progression. While several efforts have been made to predict the locations of single nucleotide variants (SNVs) at miRNA target sites and associate them with cancer risk and susceptibility, there have been few direct assessments of SNVs in both mature miRNAs and their target sites to assess their impact on miRNA function in cancers. Using genome-wide target capture of miRNAs and miRNA-binding sites followed by deep sequencing in prostate cancer cell lines, here we identified prostate cancer-specific SNVs in mature miRNAs and their target binding sites. SNV rs9860655 in the mature sequence of miR-570 was not present in benign prostate hyperplasia (BPH) tissue or cell lines but was detectable in clinical prostate cancer tissue samples and adjacent normal tissue. SLC45A3 (prostein), a putative oncogene target of miR-1178, was highly upregulated in PC3 cells harboring an miR-1178 seed sequence SNV. Finally, systematic assessment of losses and gains of miRNA targets through 3′UTR SNVs revealed SNV-associated changes in target oncogene and tumor suppressor gene expression that might be associated with prostate carcinogenesis. Further work is required to systematically assess the functional effects of miRNA SNVs.
- 2 September 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (2) , 385-394
MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAFV600E-Driven Melanoma Growth In Vivo and BRAF/MEK Inhibitor Resistance
- 2 September 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (2) , 385-394
MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAFV600E-Driven Melanoma Growth In Vivo and BRAF/MEK Inhibitor Resistance
- Open Access
Integrated RNA and metabolite profiling of urine liquid biopsies for prostate cancer biomarker discovery
Sensitive and specific diagnostic and prognostic biomarkers for prostate cancer (PCa) are urgently needed. Urine samples are a non-invasive means to obtain abundant and readily accessible “liquid biopsies”. Herein we used urine liquid biopsies to identify and characterize a novel group of urine-enriched RNAs and metabolites in PCa patients and normal individuals with or without benign prostatic disease. Differentially expressed RNAs were identified in urine samples by deep sequencing and metabolites in urine were measured by mass spectrometry. The mRNA and metabolite profiles were distinct in patients with benign and malignant disease. Integrated analysis of urinary gene expression and metabolite signatures unveiled an aberrant glutamate metabolism and tricarboxylic acid (TCA) cycle node in prostate cancer-derived cells. Functional validation supports a role for glutamate metabolism and glutamate oxaloacetate transaminase 1 (GOT1)-dependent redox balance in prostate cancer, which can be exploited for novel biomarkers and therapies.
Open AccessIntegrated RNA and metabolite profiling of urine liquid biopsies for prostate cancer biomarker discovery
Sensitive and specific diagnostic and prognostic biomarkers for prostate cancer (PCa) are urgently needed. Urine samples are a non-invasive means to obtain abundant and readily accessible “liquid biopsies”. Herein we used urine liquid biopsies to identify and characterize a novel group of urine-enriched RNAs and metabolites in PCa patients and normal individuals with or without benign prostatic disease. Differentially expressed RNAs were identified in urine samples by deep sequencing and metabolites in urine were measured by mass spectrometry. The mRNA and metabolite profiles were distinct in patients with benign and malignant disease. Integrated analysis of urinary gene expression and metabolite signatures unveiled an aberrant glutamate metabolism and tricarboxylic acid (TCA) cycle node in prostate cancer-derived cells. Functional validation supports a role for glutamate metabolism and glutamate oxaloacetate transaminase 1 (GOT1)-dependent redox balance in prostate cancer, which can be exploited for novel biomarkers and therapies.
- Open Access
- 13 February 2019
- Published by Cold Spring Harbor Laboratory in bioRxiv
- p. 548818
Exosome-mediated MIR211 modulates tumor microenvironment via the DUSP6-ERK5 axis and contributes to BRAFV600E inhibitor resistance in melanoma
The microRNA MIR211 is an important regulator of melanoma tumor cell behavior. Previous studies suggested that in certain tumors, MIR211 acted as a tumor suppressor while in others it behaved as an oncogenic regulator. When MIR211 is expressed in BRAFV600E-mutant A375 melanoma cells in mouse xenografts, it promotes aggressive tumor growth accompanied by increased cellular proliferation and angiogenesis. We demonstrate that MIR211 is transferred to adjacent cells in the tumor micro-environment via exosomes. Cross-species genome-wide transcriptomic analysis showed that human tumor-derived MIR211 interacts with the mouse transcriptome in the tumor microenvironment, and activates ERK5 signaling in human tumor cells via the modulation of a feedback loop. Human miR211 directly inhibits human DUSP6 protein phosphatase at the post-transcriptional level. We provide support for the hypothesis that DUSP6 inhibition conferred resistance of the human tumor cells to the BRAF inhibitor vemurafenib and to the MEK inhibitor cobimetinib, with associated increases in ERK5 phosphorylation. These findings are consistent with a model in which MIR211 regulates melanoma tumor proliferation and BRAF inhibitor resistance by inducing ERK5 signaling within the complex tumor microenvironment. We propose that the MIR211-ERK5 axis represents an important and sensitive regulatory arm in melanoma with potential theranostic applications.
- 13 February 2019
- Published by Cold Spring Harbor Laboratory in bioRxiv
- p. 548818
Open AccessExosome-mediated MIR211 modulates tumor microenvironment via the DUSP6-ERK5 axis and contributes to BRAFV600E inhibitor resistance in melanoma
The microRNA MIR211 is an important regulator of melanoma tumor cell behavior. Previous studies suggested that in certain tumors, MIR211 acted as a tumor suppressor while in others it behaved as an oncogenic regulator. When MIR211 is expressed in BRAFV600E-mutant A375 melanoma cells in mouse xenografts, it promotes aggressive tumor growth accompanied by increased cellular proliferation and angiogenesis. We demonstrate that MIR211 is transferred to adjacent cells in the tumor micro-environment via exosomes. Cross-species genome-wide transcriptomic analysis showed that human tumor-derived MIR211 interacts with the mouse transcriptome in the tumor microenvironment, and activates ERK5 signaling in human tumor cells via the modulation of a feedback loop. Human miR211 directly inhibits human DUSP6 protein phosphatase at the post-transcriptional level. We provide support for the hypothesis that DUSP6 inhibition conferred resistance of the human tumor cells to the BRAF inhibitor vemurafenib and to the MEK inhibitor cobimetinib, with associated increases in ERK5 phosphorylation. These findings are consistent with a model in which MIR211 regulates melanoma tumor proliferation and BRAF inhibitor resistance by inducing ERK5 signaling within the complex tumor microenvironment. We propose that the MIR211-ERK5 axis represents an important and sensitive regulatory arm in melanoma with potential theranostic applications.